在HER2接口中的热点突变会破坏结构的稳定,导致乳腺癌治疗失败
Abhijit De1, Pranay Dey, Aniketh Bishnu
1Advanced Centre for Treatment Research & Education in Cancer.
Research square
|April 1, 2025
概括
在二分化域II和IV中的新HER2突变导致对常见的乳腺癌疗法如trastuzumab产生抗性. 这些发现突出了HER2阳性乳腺癌中潜在的新治疗点和抵抗机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- HER2阳性乳腺癌 (BC) 经常复发,尽管有针对性的疗法,如trastuzumab和neratinib.
- 获得对HER2向疗法的耐药性机制尚不完全理解.
研究的目的:
- 为了识别HER2受体中的特定突变,从而产生对HER2向疗法的耐药性.
- 阐明这些已识别的突变的结构和信号后果.
主要方法:
- 对HER2二分化域II和IV的致病突变的分析.
- 近距离结合测试以评估HER2:HER3相互作用.
- 细胞检测 (生存,迁移) 和生物发光成像,以评估治疗反应.
- 下游信号通路 (ERK,AKT) 的评估.
主要成果:
- 在HER2二分化域II和IV中发现的G309A,S310Y和P523S突变破坏了HER2:HER2的结合.
- 突变促进了HER2:HER3相互作用和从ERK到AKT的信号切换.
- 这些突变在体外和体内都会对trastuzumab和neratinib产生显著的耐药性.
- 图卡替尼 (Tucatinib) 是FDA批准的HER2激酶抑制剂,对这些耐药突变物保持了有效性.
结论:
- 特定的HER2二分化域突变是对trastuzumab和neratinib耐药性的新机制.
- 准HER2二分化域可能为耐药乳腺癌提供新的治疗策略.
- 图卡替尼仍然是这些耐药突变患者的可行的治疗选择.
关键词:
在HER2阳性患者中,HER2是阳性的.乳腺癌 乳腺癌 乳腺癌分化域突变 变异域突变热点突变 热点突变在这种情况下,neratinib.这就是特拉斯图祖马布 (trastuzumab).治疗抵抗性的治疗.更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.1K
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
8.4K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Mismatch Repair
4.7K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.7K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Loss of Tumor Suppressor Gene Functions
4.7K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K
Adaptive Mechanisms in Cancer Cells
5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
